Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Egil Støre Blix
Observed names:
Blix, Egil S.,
Blix, Egil Støre,
E Blix,
E S Blix,
E. Blix,
E.S Blix,
E.S. Blix,
Egil Blix,
Egil S Blix,
Egil S. Blix
show all 10
Institutions:
University Hospital of North Norway,
UiT The Arctic University of Norway
Observed institutions:
University Hospital of North Norway,
Copenhagen University Hospital,
Rigshospitalet,
University of Oxford,
CRUK/MRC Oxford Institute for Radiation Oncology,
UiT The Arctic University of Norway
show all 6
ORCID:
0000-0001-7372-6767
Observed ORCID:
0000-0001-7372-6767
OpenAlex ID:
A5103162079
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
2020
·
H.P. Eikesdal
, S. Yndestad
, et al.
·
Annals of Oncology
·
244
PDF
LAG-3 in Non–Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival
2017
·
Sigurd M. Hald
, Mehrdad Rakaee
, et al.
·
Clinical Lung Cancer
·
83
Internal and external validation of an ESTRO delineation guideline – dependent automated segmentation tool for loco-regional radiation therapy of early breast cancer
2016
·
Ahmed R. Eldesoky
, Esben S. Yates
, et al.
·
Radiotherapy and Oncology
·
57
Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial
2025
·
Torbjørn Omland
, Siri Lagethon Heck
, et al.
·
Circulation
·
48
PDF
Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial
2021
·
A Mecinaj
, G Gulati
, et al.
·
Cardio-Oncology
·
41
PDF
Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
2023
·
Oleksii Nikolaienko
, Hans P. Eikesdal
, et al.
·
Genome Medicine
·
40
PDF
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma
2012
·
Egil S Blix
, Jonathan M Irish
, et al.
·
BMC Cancer
·
35
PDF
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
2022
·
Åslaug Helland
, Hege G. Russnes
, et al.
·
Journal of Translational Medicine
·
33
PDF
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer
2023
·
Synnøve Yndestad
, Christina Engebrethsen
, et al.
·
JCO Precision Oncology
·
32
PDF
A national precision cancer medicine implementation initiative for Norway
2022
·
Kjetil Taskén
, Hege E. G. Russnes
, et al.
·
Nature Medicine
·
30
Birth outcomes in primiparous women who were raped as adults: a matched controlled study
2010
·
H Nerum
, L Halvorsen
, et al.
·
BJOG An International Journal of Obstetrics & Gynaecology
·
30
A longitudinal study of maternal endothelial function, inflammatory response and uterine artery blood flow during the second half of pregnancy
2015
·
Kari Flo
, Egil S. Blix
, et al.
·
Acta Obstetricia Et Gynecologica Scandinavica
·
23
PDF
Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1
2017
·
Giulio Francolini
, Mette S. Thomsen
, et al.
·
Radiotherapy and Oncology
·
22
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1)
2024
·
H.O. Ohnstad
, E.S. Blix
, et al.
·
ESMO Open
·
17
PDF
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
2024
·
Katarina Puco
, Gro Live Fagereng
, et al.
·
Acta Oncologica
·
14
Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
2020
·
Thomas Helland
, Bjørn Naume
, et al.
·
Molecular Oncology
·
14
PDF
Dosimetric assessment of an Atlas based automated segmentation for loco-regional radiation therapy of early breast cancer in the Skagen Trial 1: A multi-institutional study
2017
·
Ahmed R. Eldesoky
, Giulio Francolini
, et al.
·
Clinical and Translational Radiation Oncology
·
13
PDF
Raiders of the lost mark – endothelial cells and their role in transplantation for hematologic malignancies
2016
·
Egil S. Blix
, Anne Husebekk
·
Leukemia & lymphoma/Leukemia and lymphoma
·
11
High density of TCF1+ stem-like tumor-infiltrating lymphocytes is associated with favorable disease-specific survival in NSCLC
2024
·
Dagny Førde
, Thomas Kilvær
, et al.
·
Frontiers in Immunology
·
10
PDF
5027 DBCG Skagen trial 1: Phase III randomised trial of hypo- vs standard fractionated loco-regional radiotherapy in node-positive breast cancer patients
2025
·
Birgitte Vrou Offersen
, Jan Alsner
, et al.
·
Radiotherapy and Oncology
·
9
Current treatment landscape of HR+/HER2− advanced breast cancer in the Nordics: a modified Delphi study
2023
·
Jürgen Geisler
, Peeter Karihtala
, et al.
·
Acta Oncologica
·
8
PDF
Altered BCR and CD 40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients
2012
·
Egil S. Blix
, Jonathan M. Irish
, et al.
·
British Journal of Haematology
·
7
Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma
2015
·
Egil S. Blix
, Anders B. Kildal
, et al.
·
Transplantation and Cellular Therapy
·
5
PDF
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
2026
·
Birgitte V. Offersen
, Jan Alsner
, et al.
·
Journal of Clinical Oncology
·
4
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE
2025
·
Alexios Matikas
, Bjørn Naume
, et al.
·
BMJ Open
·
4
Show more works
View as search
Works count:
68
Citation count:
890
H-index:
15
I10-index:
20
Year
Topic
Type